This application relates to various crystalline forms of (S)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren’s syndrome, arthritis, rheumatoid arthritis and psoriasis.本申請涉及處於其游離形式的(S)-N-(4-((5-(1,6-二甲基-1H-吡唑并[3,4-b]吡啶-4-基)-3-甲基-4,5,6,7-四氫-1H-吡唑并[4,3-c]吡啶-1-基)甲基)雙環[2.2.2]辛烷-1-基)啉-3-甲醯胺的不同晶型，連同組成物、其製備方法、以及其使用方法。在一些實施方式中，晶型也含有水(“水合物”)。該等材料在不同自身免疫性疾病的治療中是有用的，該等自身免疫性疾病包括全身性紅斑狼瘡、皮膚狼瘡、盤狀狼瘡、混合性結締組織病、原發性膽汁性肝硬化、免疫性血小板減少性紫癜、化膿性汗腺炎、皮肌炎、多發性肌炎、乾燥綜合征、關節炎、類風濕關節炎和銀屑病。
